CancerCare Manitoba Research Institute, CancerCare Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada.
Department of Pharmacology and Therapeutics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Autophagy. 2022 Jun;18(6):1274-1296. doi: 10.1080/15548627.2021.1973338. Epub 2021 Sep 17.
Cancer cell growth is dependent upon the sustainability of proliferative signaling and resisting cell death. Macroautophagy/autophagy promotes cancer cell growth by providing nutrients to cells and preventing cell death. This is in contrast to autophagy promoting cell death under some conditions. The mechanism regulating autophagy-mediated cancer cell growth remains unclear. Herein, we demonstrate that TSSC4 (tumor suppressing subtransferable candidate 4) is a novel tumor suppressor that suppresses cancer cell growth and tumor growth and prevents cell death induction during excessive growth by inhibiting autophagy. The oncogenic proteins ERBB2 (erb-b2 receptor tyrosine kinase 2) and the activation EGFR mutant (EGFRvIII, epidermal growth factor receptor variant III) promote cell growth and TSSC4 expression in breast cancer and glioblastoma multiforme (GBM) cells, respectively. In EGFRvIII-expressing GBM cells, knockout shifted the function of autophagy from a pro-cell survival role to a pro-cell death role during prolonged cell growth. Furthermore, the interaction of TSSC4 with MAP1LC3/LC3 (microtubule associated protein 1 light chain 3) via its conserved LC3-interacting region (LIR) contributes to its inhibition of autophagy. Finally, TSSC4 suppresses tumorsphere formation and tumor growth by inhibiting autophagy and maintaining cell survival in tumorspheres. Taken together, sustainable cancer cell growth can be achieved by autophagy inhibition via TSSC4 expression. 3-MA: 3-methyladenine; ACTB: actin beta; CQ: chloroquine; EGFRvIII: epidermal growth factor receptor variant III; ERBB2: erb-b2 receptor tyrosine kinase 2; GBM: glioblastoma multiforme; LIR: LC3-interacting region; MAP1LC3/LC3: microtubule Associated protein 1 light chain 3; TSSC4: tumor suppressing subtransferable candidate 4.
癌细胞的生长依赖于增殖信号的可持续性和对细胞死亡的抵抗。巨自噬/自噬通过向细胞提供营养并防止细胞死亡来促进癌细胞的生长。这与自噬在某些条件下促进细胞死亡形成对比。调节自噬介导的癌细胞生长的机制尚不清楚。在此,我们证明 TSSC4(肿瘤抑制可转移候选物 4)是一种新型的肿瘤抑制因子,通过抑制自噬来抑制肿瘤细胞生长和肿瘤生长并防止过度生长诱导的细胞死亡。致癌蛋白 ERBB2(erb-b2 受体酪氨酸激酶 2)和激活的 EGFR 突变体(EGFRvIII,表皮生长因子受体变体 III)分别促进乳腺癌和多形性胶质母细胞瘤(GBM)细胞中的细胞生长和 TSSC4 表达。在 EGFRvIII 表达的 GBM 细胞中,敲除使自噬的功能从促进细胞存活转变为促进细胞死亡,在延长细胞生长期间。此外,TSSC4 通过其保守的 LC3 相互作用区域(LIR)与 MAP1LC3/LC3(微管相关蛋白 1 轻链 3)相互作用,有助于抑制自噬。最后,TSSC4 通过抑制自噬并维持肿瘤球体中的细胞存活来抑制肿瘤球体形成和肿瘤生长。总之,通过 TSSC4 表达抑制自噬可以实现可持续的癌细胞生长。3-MA:3-甲基腺嘌呤;ACTB:肌动蛋白β;CQ:氯喹;EGFRvIII:表皮生长因子受体变体 III;ERBB2:erb-b2 受体酪氨酸激酶 2;GBM:多形性胶质母细胞瘤;LIR:LC3 相互作用区域;MAP1LC3/LC3:微管相关蛋白 1 轻链 3;TSSC4:肿瘤抑制可转移候选物 4。